Preclinical toxicology and pharmacology of drugs

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200422003C
Awardee
Awarding agency
Obligated
$13,945,190

Award facts

Contract value 21% obligated
  • $62,580,524.29 Current, with exercised options
  • $67,787,765.29 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers
Pricing
Cost Plus Fixed Fee
Place of performance
Menlo Park, CA 94025, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 23 -$142,342
Other Administrative Action 22 -$3,953
Other Administrative Action 21 · SRI INT. GLP, IND-directed mouse TOX study $0
Other Administrative Action 20 · Preclinical toxicology and pharmacology of drugs developed for cancer, aids,&aids related illnesses $0
Funding Only Action 19 · SRI INT. RAT BIO-distribution study, RAT GLP study, batracyclin, RAT TOX study. $508,000
Supplemental Agreement for work within scope 18 · Arra::yes::arra recovery act "in vivo screening of combinations of drugs to treat cancer $8,000,000
Funding Only Action 17 · SRI INT GLP, IND-directed mouse TOX study $140,000
Funding Only Action 16 $157,200
Funding Only Action 15 $62,000
Funding Only Action 14 $557,088
Funding Only Action 13 $85,000
Funding Only Action 12 $110,000
Funding Only Action 11 $270,000
Other Administrative Action 10 $0
Funding Only Action 9 $580,000
Funding Only Action 8 $523,092
Funding Only Action 7 $506,908
Funding Only Action 6 $506,907
Funding Only Action 5 $149,994
Funding Only Action 4 $491,418
Funding Only Action 3 $491,418
Supplemental Agreement for work within scope 2 $226,230
Funding Only Action 1 $250,000
Original award $476,230
Show all 24

About this award

Written by GovTribe AI ·

This is a $67,787,765.29 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to SRI International, a non-profit research and development institute, for preclinical toxicology and pharmacology of drugs. The contract supports biomedical research and drug development services for the NCI. SRI International has multiple indefinite delivery vehicles (IDVs) with federal agencies like the Department of Defense, NASA, and the National Institutes of Health that enable efficient procurement of its diverse technical capabilities. This contract is not a set-aside award.

Quick answers

Who was awarded contract HHSN261200422003C?

HHSN261200422003C was awarded to Sri International by National Cancer Institute (National Institutes of Health) on April 1, 2004.

How much is contract HHSN261200422003C worth?

The government has obligated $13,945,190 on HHSN261200422003C. Its current value, with exercised options, is $62,580,524. Its potential value, with all options, is $67,787,765.

Was contract HHSN261200422003C competed?

The extent of competition for HHSN261200422003C was full and open competition. The government received 8 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login